Jie-Bin Lew

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8539555/publications.pdf Version: 2024-02-01



LIE-RIN LEW

#	Article	IF	CITATIONS
1	Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncology, The, 2019, 20, 394-407.	10.7	279
2	The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health, The, 2019, 4, e19-e27.	10.0	268
3	The burden of cervical cancer in China: Synthesis of the evidence. International Journal of Cancer, 2012, 130, 641-652.	5.1	127
4	Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health, The, 2017, 2, e96-e107.	10.0	124
5	Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lancet Public Health, The, 2017, 2, e331-e340.	10.0	114
6	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. The Lancet Gastroenterology and Hepatology, 2021, 6, 304-314.	8.1	99
7	Trends in Colon and Rectal Cancer Incidence in Australia from 1982 to 2014: Analysis of Data on Over 375,000 Cases. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 83-90.	2.5	81
8	Foraging in honeybees—when does it pay to dance?. Behavioral Ecology, 2008, 19, 255-261.	2.2	76
9	Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine, 2011, 29, 2487-2494.	3.8	69
10	Will cervical screening remain costâ€effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. International Journal of Cancer, 2016, 139, 2771-2780.	5.1	62
11	The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine, 2011, 29, 9112-9122.	3.8	58
12	Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: Example from Australia. PLoS ONE, 2018, 13, e0185332.	2.5	52
13	Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer, 2011, 11, 239.	2.6	51
14	SeqVis: Visualization of compositional heterogeneity in large alignments of nucleotides. Bioinformatics, 2006, 22, 2162-2163.	4.1	50
15	Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. PLoS ONE, 2016, 11, e0151619.	2.5	49
16	The predicted impact of vaccination on human papillomavirus infections in Australia. International Journal of Cancer, 2008, 123, 1854-1863.	5.1	48
17	Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health, The, 2016, 1, e66-e75.	10.0	37
18	Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC Health Services Research, 2016, 16, 147.	2.2	36

Jie-Bin Lew

#	Article	IF	CITATIONS
19	Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey. Cancer, 2021, 127, 1880-1893.	4.1	36
20	Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health, 2010, 10, 734.	2.9	35
21	Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ, The, 2012, 345, e7086-e7086.	6.0	35
22	Modeling the Adenoma and Serrated Pathway to Colorectal CAncer (ASCCA). Risk Analysis, 2014, 34, 889-910.	2.7	35
23	Impact of HPV sample selfâ€collection for underscreened women in the renewed Cervical Screening Program. Medical Journal of Australia, 2016, 204, 194-194.	1.7	35
24	Estimation of the costs of cervical cancer screening, diagnosis and treatment in rural Shanxi Province, China: a micro-costing study. BMC Health Services Research, 2012, 12, 123.	2.2	34
25	Factors associated with participation in colorectal cancer screening in Australia: Results from the 45 and Up Study cohort. Preventive Medicine, 2018, 106, 185-193.	3.4	29
26	Evaluation of the benefits, harms and costâ€effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. International Journal of Cancer, 2018, 143, 269-282.	5.1	28
27	Benefits, Harms, and Cost-Effectiveness of Potential Age Extensions to the National Bowel Cancer Screening Program in Australia. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1450-1461.	2.5	26
28	Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. PLoS ONE, 2017, 12, e0163509.	2.5	26
29	Long-Term Impact of the Dutch Colorectal Cancer Screening Program on Cancer Incidence and Mortality—Model-Based Exploration of the Serrated Pathway. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 135-144.	2.5	25
30	How will transitioning from cytology to <scp>HPV</scp> testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in <scp>A</scp> ustralia, a high vaccination coverage country. International Journal of Cancer, 2017, 141, 2410-2422.	5.1	25
31	Could HPV Testing on Self-collected Samples Be Routinely Used in an Organized Cervical Screening Program? A Modeled Analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 268-277.	2.5	24
32	Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. Public Health Research and Practice, 2019, 29, .	1.5	24
33	The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis. British Journal of Radiology, 2016, 89, 20150910.	2.2	21
34	Expenditure and resource utilisation for cervical screening in Australia. BMC Health Services Research, 2012, 12, 446.	2.2	18
35	Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment. PLoS ONE, 2020, 15, e0227899.	2.5	16
36	Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecologic Oncology, 2019, 152, 465-471.	1.4	14

Jie-Bin Lew

#	Article	IF	CITATIONS
37	Validation of Microsimulation Models against Alternative Model Predictions and Long-Term Colorectal Cancer Incidence and Mortality Outcomes of Randomized Controlled Trials. Medical Decision Making, 2020, 40, 815-829.	2.4	14
38	Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities. Cancer Epidemiology, 2015, 39, 600-611.	1.9	13
39	A revision of sexual mixing matrices in models of sexually transmitted infection. Statistics in Medicine, 2012, 31, 3419-3432.	1.6	9
40	Resilience of a FIT screening programme against screening fatigue: a modelling study. BMC Public Health, 2016, 16, 1009.	2.9	8
41	Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study. Journal of Medical Screening, 2022, 29, 72-83.	2.3	8
42	The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications. Gynecologic Oncology, 2019, 152, 472-479.	1.4	7
43	Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities: Example from New Zealand. Vaccine, 2018, 36, 6314-6324.	3.8	6
44	The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study. Journal of Cancer Policy, 2022, 32, 100325.	1.4	6
45	Development and application of a framework to estimate health care costs in China: The cervical cancer example. PLoS ONE, 2019, 14, e0222760.	2.5	5
46	Health economic evaluation of primary human papillomavirus screening in urban populations in China. Cancer Epidemiology, 2021, 70, 101861.	1.9	5
47	Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia. PLoS ONE, 2021, 16, e0260088.	2.5	5
48	Trends in colon and rectal cancer mortality in Australia from 1972 to 2015 and associated projections to 2040. Scientific Reports, 2022, 12, 3994.	3.3	5
49	Cost-effectiveness estimates: the need for complete reporting – Authors' reply. Lancet Public Health, The, 2017, 2, e212.	10.0	2
50	Impact of Scaled up Human Papillomavirus Vaccination and Cervical Screening and the Potential for Global Elimination of Cervical Cancer in 181 Countries, 2020–99: A Modelling Study. Obstetrical and Gynecological Survey, 2019, 74, 345-347.	0.4	1
51	Pathways to a cancer-free future: a protocol for modelled evaluations to minimise the future burden of colorectal cancer in Australia. BMJ Open, 2020, 10, e036475.	1.9	1
52	Towards global elimination of cervical cancer in all groups of women – Authors' reply. Lancet Oncology, The, 2019, 20, e239.	10.7	0